Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HT-101 + HT-102
- Development stage
- Phase 2
- Lead developer
- HepaThera
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
HT-101 + HT-102 is a combination therapy developed by HepaThera Biotech for the treatment of chronic hepatitis B (CHB), aiming for a functional cure. The regimen consists of HT-101, a GalNAc-conjugated small interfering RNA (siRNA) that targets the hepatitis B virus (HBV) S region to silence viral transcripts and reduce antigen production, and HT-102 (also known as BM012), a neutralizing antibody designed to clear circulating viral proteins like HBsAg. By combining intracellular viral suppression with extracellular protein clearance, the therapy seeks to restore the host's immune response against HBV. It is currently in Phase 2 clinical trials.
02
Targets
HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on HT-101 + HT-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HT-101 + HT-102.